Biodesix (BDSX) News
NASDAQ: BDSXHealth CareMedical SpecialitiesUSD
26.02+0.39 (+1.52%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BDSX news summary
We found 4 recent headlines mentioning Biodesix (BDSX): 1 in the past week and 3 in the past 30 days, most often from Nasdaq. For price context, BDSX is up 1.52% at $26.02. The most recent story, "Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus", was published by Nasdaq on Oct 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Biodesix headlines
- Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in FocusTMO, CRCT and SHOP delivered strong gains as Zacks highlighted standout performers across its research portfolios.NasdaqICE, FAST, DGX, TMO
- Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive TestsBDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.NasdaqBDSX, TMO, BIO, VCYT
- Biodesix Reveals Two Developing MRD Solution Collaborations With Bio-Rad And Thermo Fisher(RTTNews) - Biodesix Inc. (BDSX), a diagnostic solutions company, last week reported strategic progress for two programmes regarding Molecular Residual Disease (MRD) solutions for cancer diagnosis.…NasdaqBDSX, BIO, TMO
- MDLN Gets FDA Warning for Quality Lapses in Angiographic SyringesMDLN faces FDA warning over cGMP lapses in angiographic syringes, citing weak quality controls, CAPA gaps and design flaws despite escalating share price.NasdaqGMED, PACB, BDSX, MDLN